Medica Coverage Policy

<table>
<thead>
<tr>
<th>Policy Name:</th>
<th>Serial Dilution Endpoint Titration for Diagnosis and Treatment of Airborne Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective Date:</td>
<td>10/15/2018</td>
</tr>
</tbody>
</table>

**Important Information – Please Read Before Using This Policy**

These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage. With respect to Medicare and Minnesota Health Care Programs, this policy will apply unless those programs require different coverage. Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica coverage policy may call the Medica Provider Service Center toll-free at 1-800-458-5512.

Medica coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care and treatment.

**Coverage Policy**

Serial dilution endpoint titration for airborne allergy is investigative and unproven and therefore **NOT COVERED**. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the efficacy or effects on health care outcomes.

**Note:** This policy is no longer scheduled for routine review of the scientific literature.

**Description**

Serial dilution endpoint titration (SDET), also referred to as skin endpoint titration or intradermal dilutional testing, is a form of intradermal skin testing proposed to diagnose and treat allergy disorders. SDET involves two steps. In the first step, the antigen is administered in successive injections using increasing doses of the antigen with each injection to determine the concentration at which the reaction changes from negative to positive (the lowest dilution or “endpoint”). The second step uses the endpoint dilution as the starting dilution for immunotherapy treatment. Over the course of therapy, the antigen concentration is incrementally increased. SDET is performed in the clinical setting, and more than one allergen can be tested in this manner.

**FDA Approval**

SDET is a method of administering an intradermal skin test for allergy in a physician’s office. Therefore, the technique is not subject to FDA approval.

**Prior Authorization**

Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.
Medica Coverage Policy

Coding Considerations
Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes
- 95027 - Intracutaneous (intradermal) tests, sequential and incremental, with allergenic extracts form airborne allergens, immediate type reaction, including test interpretation and report by a physician, specify number of tests.

Original Effective Date: 2/1/2004
Re-Review Date(s): 6/15/2009
6/26/2012
7/15/2015
7/18/2018
2/28/2020 – administrative update; format

© 2004–2020 Medica. Medica® is a registered service mark of Medica Health Plans. “Medica” refers to the family of health services companies that includes Medica Health Plans, Medica Community Health Plan, Medica Insurance Company, Medica Self-Insured, MMSI, Inc. d/b/a Medica Health Plan Solutions, Medica Health Management, LLC and the Medica Foundation.